Royalty Pharma plc (NASDAQ:RPRX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Royalty Pharma plc (NASDAQ:RPRX) have been assigned a consensus rating of “Moderate Buy” from the five research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $41.80.

Several equities analysts have commented on the company. UBS Group downgraded Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price objective on the stock. in a research report on Monday, June 3rd. Morgan Stanley upped their price target on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. Bank of America decreased their price objective on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a report on Friday, April 12th. Finally, StockNews.com cut shares of Royalty Pharma from a “buy” rating to a “hold” rating in a report on Friday, May 10th.

Institutional Investors Weigh In On Royalty Pharma

A number of large investors have recently modified their holdings of the business. Versant Capital Management Inc boosted its stake in Royalty Pharma by 5,215.0% in the 2nd quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 1,043 shares in the last quarter. Gladius Capital Management LP purchased a new position in shares of Royalty Pharma in the second quarter worth $32,000. Fidelis Capital Partners LLC acquired a new stake in shares of Royalty Pharma during the first quarter worth $46,000. GAMMA Investing LLC grew its holdings in shares of Royalty Pharma by 172.5% during the first quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 1,037 shares during the last quarter. Finally, Allworth Financial LP increased its position in shares of Royalty Pharma by 76.7% in the 4th quarter. Allworth Financial LP now owns 1,684 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 731 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

Shares of NASDAQ:RPRX opened at $28.79 on Friday. The company has a current ratio of 12.52, a quick ratio of 12.52 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $17.20 billion, a price-to-earnings ratio of 21.49, a PEG ratio of 3.78 and a beta of 0.46. Royalty Pharma has a 12 month low of $25.20 and a 12 month high of $31.66. The firm’s 50-day moving average is $26.98 and its 200 day moving average is $28.40.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.02. Royalty Pharma had a return on equity of 22.94% and a net margin of 35.70%. The firm had revenue of $568.00 million for the quarter, compared to analysts’ expectations of $671.45 million. During the same quarter in the prior year, the firm posted $1.60 earnings per share. Research analysts predict that Royalty Pharma will post 4.01 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 13th. Shareholders of record on Friday, August 16th will be paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 2.92%. The ex-dividend date of this dividend is Friday, August 16th. Royalty Pharma’s dividend payout ratio (DPR) is presently 62.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.